Results 141 to 150 of about 82,336 (259)

Second delivery rates and recurrence of adverse pregnancy outcomes in women with systemic lupus erythematosus: a nationwide population-based cohort study. [PDF]

Rheumatology (Oxford)
Antovic A, Nguyen NV, Gunnarsson I, Sandström A, Arkema EV.   +4 more
europepmc   +1 more source

Potential contribution of biomass gasification‐based technology in energy transition: a technical review coupled with bibliometric studies

Biofuels, Bioproducts and Biorefining, EarlyView.
Abstract Biomass gasification technology has been extensively researched around the world; however, there is a need to evaluate the current research landscape and evolutionary direction of research in the broader context of energy transition. A systematic bibliometric analysis of the Web of Science database was performed for articles that fall within ...
Olasunkanmi Opeoluwa Adeoye, Electo Eduardo Silva Lora, Rubenildo Vieira Andrade, Leonardo Peña Pupo, René Lesme Jaén, Osvaldo José Venturini   +5 more
wiley   +1 more source

Potential Roles of Prostaglandins PGD2, PGJ2, and PGE2 in the Pathogenesis of Systemic Lupus Erythematosus. [PDF]

Int J Mol Sci
Xu T, Luo XM.
europepmc   +1 more source

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

British Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun, Jingrong Yang, Lei Wan, Xia Xu, Jing Wang   +4 more
wiley   +1 more source

Clinical predictors for bloodstream infection in systemic lupus erythematosus. [PDF]

Ann Med
Ye M, He Y, Yi S, Liu P, Zhao C, Chen Y, Li L.   +6 more
europepmc   +1 more source

Targeting neutrophil extracellular traps in metabolic and immune niche: Nanomaterials for diabetes tissue regeneration

BMEMat, EarlyView.
The effects of NETs on regeneration of various diabetic tissues, and strategies targeting NETs for diabetes tissue regeneration. In the diabetic environment, NETs undergo complex metabolic and immune reprogramming, leading to dynamic changes in antibacterial and proinflammatory functions, and affecting regeneration of multiple systemic tissues.
Xinyi Jiang, Muxin Yue, Kai Mao, Boon Chin Heng, Noor Azlin Yahya, Yunsong Liu, Zheng Li   +6 more
wiley   +1 more source

Systematic dysregulation of immune-related alternative polyadenylation in systemic lupus erythematosus contributes to patient stratification. [PDF]

J Transl Autoimmun
Chen Z, Shi J, Meng Y, Xiong S, Ruan H.
europepmc   +1 more source

Surgical management of persistent gingival recession after sepsis‐associated gingival necrosis in a patient with systemic lupus erythematosus: A case report

Clinical Advances in Periodontics, EarlyView.
Abstract Background Sepsis‐associated gingival necrosis is an uncommon oral manifestation that may result in extensive gingival recession after the resolution of the acute phase. Methods This report presents the 2‐year follow‐up of periodontal management in a 38‐year‐old woman with systemic lupus erythematosus, who developed septic shock accompanied by
Risako Mikami, Koji Mizutani, Ruriko Mizuno, Yuji Kabasawa, Koichiro Matsuo   +4 more
wiley   +1 more source

Gene expression profiling of dendritic cell tolerance dysfunction in women with systemic lupus erythematosus. [PDF]

Front Immunol
Hernández-Ledesma AL, Coss-Navarrete EL, Salazar-Magaña S, Ramírez-Espinosa D, Tinajero-Nieto L, Torres-Valdez E, Peña-Ayala AH, Félix-Rodriguez G, Frontana-Vázquez G, García Sotelo JS, Thomas-Chollier M, Trynka G, Rosetti F, Fernandez-Valverde SL, Gutiérrez-Arcelus M, Alpízar-Rodríguez D, Medina-Rivera A.   +16 more
europepmc   +1 more source

Anifrolumab Dose Regimen Selection for a Phase 3 Trial in Lupus Nephritis

Clinical Pharmacology &Therapeutics, EarlyView.
In patients with systemic lupus erythematosus (SLE), increased type I interferon signaling is associated with increased disease activity across organs, including in the kidney, which can cause lupus nephritis (LN). Anifrolumab, which abrogates type I interferon signaling, is an approved treatment for moderate to severe SLE.
Joachim Almquist, Yen Lin Chia, Raj Tummala, Lynn Bertagnolli, David Jayne, Weifeng Tang, Catharina Lindholm   +6 more
wiley   +1 more source